A. Nicholas

发表

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Interim analysis and biomarker data from a multicenter study (LCMC3).

V. Rusch, Bruce E. Johnson, I. Wistuba, 2019, Journal of Clinical Oncology.

Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): Initial results from a multicenter study (LCMC3).

M. Kris, V. Rusch, Bruce E. Johnson, 2018 .

Plasma-Based Measurements of Tumor Heterogeneity Correlate with Clinical Outcomes in Metastatic Colorectal Cancer

H. Hurwitz, S. Yaung, J. Bendell, 2022, Cancers.

PS01.05 Surgical and Clinical Outcomes With Neoadjuvant Atezolizumab in Resectable Stage IB–IIIB NSCLC: LCMC3 Trial Primary Analysis

M. Kris, V. Rusch, I. Wistuba, 2021 .

Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

M. Kris, V. Rusch, I. Wistuba, 2022, Nature Medicine.

MA04.09 Neoadjuvant Atezolizumab in Resectable Non-Small Cell Lung Cancer (NSCLC): Updated Results from a Multicenter Study (LCMC3)

M. Kris, V. Rusch, I. Wistuba, 2018, Journal of Thoracic Oncology.

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

P. Galle, R. Lencioni, M. Ducreux, 2021, Journal of Clinical Oncology.

Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

M. Kudo, H. Toh, P. Merle, 2022, Liver Cancer.

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

P. Galle, R. Lencioni, A. Zhu, 2021 .

Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

N. Ibrahim, N. Lin, M. Pegram, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

M. Kudo, P. Galle, M. Ducreux, 2021, Journal of hepatology.

Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study.

M. Kris, V. Rusch, I. Wistuba, 2021 .

Disease Monitoring Using Post-induction Circulating Tumor DNA Analysis Following First-Line Therapy in Patients with Metastatic Colorectal Cancer

H. Hurwitz, S. Yaung, J. Bendell, 2020, Clinical Cancer Research.

1O Dynamic circulating tumour DNA (ctDNA) response to neoadjuvant (NA) atezolizumab (atezo) and surgery (surg) and association with outcomes in patients (pts) with NSCLC

M. Kris, P. Bunn, D. Kwiatkowski, 2021, Annals of Oncology.

MA09.01 LCMC3: Immune Cell Subtypes Predict Nodal Status and Pathologic Response After Neoadjuvant Atezolizumab in Resectable NSCLC

M. Kris, G. Lozanski, M. Seweryn, 2021, Journal of Thoracic Oncology.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

J. Reeves, B. Somer, H. Lenz, 2019, The oncologist.

OA06.06 Clinical/Biomarker Data for Neoadjuvant Atezolizumab in Resectable Stage IB-IIIB NSCLC: Primary Analysis in the LCMC3 Study

M. Kris, V. Rusch, I. Wistuba, 2021 .

P2.04-88 Surgical Outcomes of a Multicenter Phase II Trial of Neoadjuvant Atezolizumab in Resectable Stages IB-IIIB NSCLC: Update on LCMC3 Clinical Trial

M. Kris, V. Rusch, I. Wistuba, 2019, Journal of Thoracic Oncology.

OA13.07 Neoadjuvant Atezolizumab in Resectable NSCLC Patients: Immunophenotyping Results from the Interim Analysis of the Multicenter Trial LCMC3

M. Kris, V. Rusch, I. Wistuba, 2019, Journal of Thoracic Oncology.

IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)

M. Ducreux, A. Cheng, S. Qin, 2021, Zeitschrift für Gastroenterologie.

Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC).

N. Ibrahim, M. Pegram, A. Stein, 2017 .

Abstract P1-18-03: Pertuzumab (P) plus high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression after radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC): Primary efficacy analysis results from the phase II PATRICIA study

N. Ibrahim, M. Pegram, A. Nicholas, 2020 .

Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

M. Kris, V. Rusch, I. Wistuba, 2022, The Journal of thoracic and cardiovascular surgery.